



## Curriculum Vitae

### Personal information Peter Van Meer

#### Work experience

1. Employer: Medicines Evaluation Board
  - Start date: 042014
  - End date:
  - Position: Senior assessor
  - Activities: Primary assessment of Centralised Procedures, PRIME applications, Scientific Advice procedures, Decentralised and National procedures across all therapeutic classes. Assessment of paediatric investigation plans and paediatric scientific advice procedures for the Paediatric committee nonclinical working group (EMA PDCO NCWg) Secretary of the MEB Scientific Committee
  - Country: Netherlands
2. Employer: Utrecht University
  - Start date: 082013
  - End date: 122021
  - Position: Project manager
  - Activities: Co\_promotor of 2 PhD candidates which evaluate the value of animal models of efficacy in drug development to identify 3Rs opportunities. Co\_promotor of a PhD candidate on a project to optimise biosimilar applications based on the quality characterisation of biosimilar products.
  - Country: Netherlands
3. Employer: Radboud Universiteit Nijmegen
  - Start date: 082021
  - End date:
  - Position: Visiting scientist
  - Activities: Co\_promotor of a PhD candidate on the project 'Regulatory opportunities and challenges to improve non\_clinical requirements in drug development'
  - Country: Netherlands

#### Education and training

1. Subject: Utrecht University
  - Start date: 042009
  - End date: 102013
  - Qualification: PhD
  - Organisation: Regulatory Science, Non\_clinical drug development, monoclonal antibodies, non\_human primates, immunogenicity, predictivity of animal models
  - Country: Netherlands
2. Subject: Vrije Universiteit Amsterdam
  - Start date: 052004
  - End date: 022009
  - Qualification: MSc
  - Organisation: Drug disposition and safety (major in molecular pharmacology)
  - Country: Netherlands
3. Subject: Avans Hogeschool
  - Start date: 092000
  - End date: 082004
  - Qualification: BAs
  - Organisation: Organic Chemistry
  - Country: Netherlands

#### Additional information

##### Publications

Schneider MR, Oelgeschlaeger M, Burgdorf T, van Meer P, Theunissen P, Kienhuis AS, Piersma AH, Vandebriel RJ. Applicability of organ\_on\_chip systems in toxicology and pharmacology. *Crit Rev Toxicol.* 2021 Jul;51(6):540-554. doi: 10.1080/10408444.2021.1953439. Epub 2021 Aug 31. PMID: 34463591. van Meer P, Theunissen P, van den Hoorn T, Herberts C, van der Laan JW. Animal\_free applications in the development of cell\_based therapies. *Br J Clin Pharmacol.* 2021 Jun;87(6):2425-2427. doi: 10.1111/bcp.14544. Epub 2020 Sep 15. PMID: 32935350. Dekker MJH, de Vries ST, Versantvoort CHM, Drost\_van Velze EGE, Bhatt M, van Meer PJK, Havinga IK, Gispen\_de Wied CC, Mol PGM. Sex Proportionality in Pre\_clinical and Clinical Trials: An Evaluation of 22 Marketing Authorization Application Dossiers Submitted to the European Medicines Agency. *Front Med (Lausanne).* 2021 Mar 11;8:643028. doi: 10.3389/fmed.2021.643028. PMID: 33791329; PMCID: PMC8006272. Veening\_Griffioen DH, Ferreira GS, Boon WPC, Gispen\_de Wied CC, Schellekens H, Moors EHM, Van Meer PJK. Tradition, not science, is the basis of animal model selection in translational and applied research. *ALTEX.* 2021;38(1):49-62. doi: 10.14573/altex.2003301. Epub 2020 Jun 22. PMID: 32591838. Ferreira GS, Veening\_Griffioen DH, Boon WPC, Moors EHM, van Meer PJK. Levelling the Translational Gap for Animal to Human Efficacy Data. *Animals (Basel).* 2020 Jul 15;10(7):1199. doi: 10.3390/ani10071199. PMID: 32679706; PMCID: PMC7401509. Ferreira GS, Veening\_Griffioen DH, Boon WPC, Hooijmans CR, Moors EHM, Schellekens H, van Meer PJK. Comparison of drug efficacy in two animal models of type 2 diabetes: A systematic review and meta\_analysis. *Eur J Pharmacol.* 2020 Jul 15;879:173153. doi: 10.1016/j.ejphar.2020.173153. Epub 2020 Apr 28. PMID: 32360835. Veening\_Griffioen DH, Ferreira GS, van Meer PJK, Boon WPC, Gispen\_de Wied CC, Moors EHM, Schellekens H. Are some animal models more equal than others? A case study on the translational value of animal models of efficacy for Alzheimer's disease. *Eur J Pharmacol.* 2019 Sep 15;859:172524. doi: 10.1016/j.ejphar.2019.172524. Epub 2019 Jul 7. PMID: 31291566. Ferreira GS,

Veening\_Griffioen DH, Boon WPC, Moors EHM, Gispens\_de Wied CC, Schellekens H, van Meer PJK. A standardised framework to identify optimal animal models for efficacy assessment in drug development. *PLoS One*. 2019 Jun 13;14(6):e0218014. doi: 10.1371/journal.pone.0218014. Erratum in: *PLoS One*. 2019 Jul 22;14(7):e0220325. PMID: 31194784; PMCID: PMC6563989. Hulshof TA, Zuidema SU, van Meer PJK, Gispens\_de Wied CC, Luijendijk HJ. Baseline imbalances and clinical outcomes of atypical antipsychotics in dementia: A meta\_epidemiological study of randomized trials. *Int J Methods Psychiatr Res*. 2019 Mar;28(1):e1757. doi: 10.1002/mpr.1757. Epub 2018 Dec 4. PMID: 30515916; PMCID: PMC6587552. van Meer PJ, Graham ML, Schuurman HJ. The safety, efficacy and regulatory triangle in drug development: Impact for animal models and the use of animals. *Eur J Pharmacol*. 2015 Jul 15;759:3\_13. doi: 10.1016/j.ejphar.2015.02.055. Epub 2015 Mar 27. PMID: 25818943. van Meer PJ, Ebberts HC, Kooijman M, Gispens\_de Wied CC, Silva\_Lima B, Moors EH, Schellekens H. Contribution of animal studies to evaluate the similarity of biosimilars to reference products. *Drug Discov Today*. 2015 Apr;20(4):483\_90. doi: 10.1016/j.drudis.2014.11.009. Epub 2014 Nov 20. PMID: 25463036. Kooijman M, van Meer PJ, Gispens\_de Wied CC, Moors EH, Hekkert MP, Schellekens H. The risk\_based approach to ATMP development \_ generally accepted by regulators but infrequently used by companies. *Regul Toxicol Pharmacol*. 2013 Nov;67(2):221\_5. doi: 10.1016/j.yrtph.2013.07.014. Epub 2013 Aug 7. PMID: 23933031. van Meer PJ, Kooijman M, van der Laan JW, Moors EH, Schellekens H. The value of non\_human primates in the development of monoclonal antibodies. *Nat Biotechnol*. 2013 Oct;31(10):882\_3. doi: 10.1038/nbt.2709. PMID: 24104750. van Meer PJ, Kooijman M, Brinks V, Gispens\_de Wied CC, Silva\_Lima B, Moors EH, Schellekens H. Immunogenicity of mAbs in non\_human primates during nonclinical safety assessment. *MAbs*. 2013 Sep\_Oct;5(5):810\_6. doi: 10.4161/mabs.25234. Epub 2013 Jun 6. PMID: 23924803; PMCID: PMC3851233. Ebberts HC, van Meer PJ, Moors EH, Mantel\_Teeuwisse AK, Leufkens HG, Schellekens H. Measures of biosimilarity in monoclonal antibodies in oncology: the case of bevacizumab. *Drug Discov Today*. 2013 Sep;18(17\_18):872\_9. doi: 10.1016/j.drudis.2013.05.004. Epub 2013 May 18. PMID: 23688584. van Meer PJ, Kooijman M, Gispens\_de Wied CC, Moors EH, Schellekens H. The ability of animal studies to detect serious post marketing adverse events is limited. *Regul Toxicol Pharmacol*. 2012 Dec;64(3):345\_9. doi: 10.1016/j.yrtph.2012.09.002. Epub 2012 Sep 12. PMID: 22982732. Kooijman M, van Meer PJ, Moors EH, Schellekens H. Thirty years of preclinical safety evaluation of biopharmaceuticals: Did scientific progress lead to appropriate regulatory guidance? *Expert Opin Drug Saf*. 2012 Sep;11(5):797\_801. doi: 10.1517/14740338.2012.712110. Epub 2012 Aug 6. PMID: 22861668. Siegel JA, Benice TS, Van Meer P, Park BS, Raber J. Acetylcholine receptor and behavioral deficits in mice lacking apolipoprotein E. *Neurobiol Aging*. 2011 Jan;32(1):75\_84. doi: 10.1016/j.neurobiolaging.2008.12.006. Epub 2009 Jan 28. PMID: 19178986; PMCID: PMC3172704. Acevedo SF, Pfankuch T, van Meer P, Raber J. Role of histamine in short\_ and long\_term effects of methamphetamine on the developing mouse brain. *J Neurochem*. 2008 Nov;107(4):976\_86. doi: 10.1111/j.1471\_4159.2008.05673.x. Epub 2008 Sep 11. PMID: 18786166; PMCID: PMC3172696. Villasana L, Poage C, van Meer P, Raber J. Passive avoidance learning and memory of 56Fe sham\_irradiated and irradiated human apoE transgenic mice. *Radiat Biol Radioecol*. 2008 Mar\_Apr;48(2):167\_70. PMID: 18666648. van Meer P, Pfankuch T, Raber J. Reduced histamine levels and H3 receptor antagonist\_induced histamine release in the amygdala of ApoE\_/ mice. *J Neurochem*. 2007 Oct;103(1):124\_30. doi: 10.1111/j.1471\_4159.2007.04705.x. Epub 2007 Jun 15. PMID: 17573822. van Meer P, Acevedo S, Raber J. Impairments in spatial memory retention of GFAP\_apoE4 female mice. *Behav Brain Res*. 2007 Jan 25;176(2):372\_5. doi: 10.1016/j.bbr.2006.10.024. Epub 2006 Nov 28. PMID: 17126420; PMCID: PMC1950679. Van Meer P, Raber J. Mouse behavioural analysis in systems biology. *Biochem J*. 2005 Aug 1;389(Pt 3):593\_610. doi: 10.1042/BJ20042023. PMID: 16035954; PMCID: PMC1180709.

## Projects

## Memberships

Member of the EMA Non-clinical Working Party, member of the EMA 3Rs Working Party, member of the Regulatory Science Network Netherlands advisory group (RSNN, vice\_chair from 2018\_2021), member of the MEB Scientific Committee, member of the ZonMW 3R Scientific Committee

## Other Relevant Information